Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systolic Dysfunction Clear all
Completed Phase 4 Interventional Results available

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

NCT00523549
View directory record Official record
Conditions
Hypertension, Diastolic Dysfunction
Interventions
valsartan, amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
USA, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction

NCT00387621
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Nesiritide, Placebo, Saline
Drug
Lead sponsor
Horng Chen
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone

NCT01807221
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo, Inspra (eplerenone)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,066 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 7, 2026, 3:37 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Association of PICP Serum Marker in Patients With LVSD

NCT00232388
View directory record Official record
Conditions
Systolic Dysfunction
Interventions
Blood draw
Procedure
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

NCT01786512
View directory record Official record
Conditions
Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions
Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
38
States / cities
Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary Bypass

NCT02025621
View directory record Official record
Conditions
Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome
Interventions
Levosimendan, Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
882 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
49
States / cities
Burlington, Alabama • Huntsville, Alabama • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 4 Interventional

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

NCT00082589
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
Eplerenone
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
53
States / cities
Castro Valley, California • San Diego, California • Santa Rosa, California + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2020 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Impact of Diabetes on Left Ventricular Remodeling

NCT01052272
View directory record Official record
Conditions
Diabetes
Interventions
Ramipril, Candesartan cilexetil, Allopurinol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
21 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting No phase listed Observational

Multimodality Evaluation of Left Ventricular Remodeling In Mitral Regurgitation: A Pilot Study

NCT06770062
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Terminated Not applicable Interventional

Neuromodulation of Inflammation and Vascular Function in Systolic Heart Failure

NCT03945058
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
TVS, SHAM
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients

NCT00689819
View directory record Official record
Conditions
Hypertension, High Blood Pressure, Ventricular Hypertrophy, Diastolic Dysfunction, Systolic Dysfunction
Interventions
Exercise, Weight Loss, Low Sodium Diet, Smoking Cessation, Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)
Behavioral · Drug
Lead sponsor
Wayne State University
Other
Eligibility
35 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2013 · Synced Sep 7, 2026, 3:37 PM EDT
Not listed No phase listed Observational

CarDiac MagnEtic Resonance for Primary Prevention Implantable CardioVerter DebrillAtor ThErapy: an International Registry (DERIVATE)

NCT03352648
View directory record Official record
Conditions
Heart Failure, Left Ventricular Systolic Dysfunction
Interventions
Not listed
Lead sponsor
Gianluca Pontone, MD, PhD
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Sep 7, 2026, 3:37 PM EDT
Completed No phase listed Observational

The Role of Heart Stiff and Weak Atrium on Exercise Capacity in Patients With Hypertrophic Cardiomyopathy

NCT00074880
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional

ECG AI-Guided Screening for Low Ejection Fraction

NCT04000087
View directory record Official record
Conditions
Asymptomatic Left Ventricular Systolic Dysfunction (Disorder), Heart Failure
Interventions
AI-enabled ECG-based Screening Tool
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)

NCT01970176
View directory record Official record
Conditions
Cardiomyopathy, Renal Impairment
Interventions
Tadalafil, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 3 Interventional Results available

RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial

NCT00358215
View directory record Official record
Conditions
Heart Failure, Anemia, Cardiovascular Disease, Ventricular Dysfunction, Congestive Heart Failure
Interventions
Darbepoetin alfa, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
2,278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
254
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 195 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 3 Interventional

Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg

NCT00272805
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
carvedilol
Drug
Lead sponsor
Cardiovascular Clinical Sciences Inc
Industry
Eligibility
18 Years to 90 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
54
States / cities
Mobile, Alabama • Sierra Vista, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Systolic Blood Pressure Intervention Trial

NCT01206062
View directory record Official record
Conditions
Hypertension
Interventions
Intensive control of SBP, Standard control of SBP
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
50 Years and older
Enrollment
9,361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Not applicable Interventional

The SMART-LV Pilot Study

NCT05630170
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction
Interventions
AI-ECG
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 7, 2026, 3:37 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

NCT07188805
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions
Finerenone (Kerendia, BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 17 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 7, 2026, 3:37 PM EDT
Completed No phase listed Observational

Effect of Post Discharge Follow-up on Readmission Rates for Congestive Heart Failure Patients

NCT01529463
View directory record Official record
Conditions
Congestive Heart Failure, Systolic Dysfunction
Interventions
Not listed
Lead sponsor
Trinity Health Of New England
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 28, 2013 · Synced Sep 7, 2026, 3:37 PM EDT
Completed Phase 4 Interventional Results available

A Study of Ivabradine in African-American/ Black Subjects With Heart Failure and Left Ventricular Systolic Dysfunction.

NCT03456856
View directory record Official record
Conditions
Heart Failure (HF)
Interventions
Ivabradine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Wilmington, Delaware • Detroit, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 7, 2026, 3:37 PM EDT
Completed No phase listed Observational

Patient and Physician Survey Determinants of Appropriate ICD Utilization

NCT01514773
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Not listed
Lead sponsor
Todd M Koelling, MD
Other
Eligibility
18 Years and older
Enrollment
452 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 7, 2026, 3:37 PM EDT
Active, not recruiting No phase listed Observational

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

NCT05036252
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 7, 2026, 3:37 PM EDT